In this context, HDAC6 selective inhibitors have proven efficacy in downregulating PD-L1 expression both on certain types of tumor cells and myeloid cells, such as DCs and macrophages (8, 16, 17, 19). The gene discussed is HDAC6; the disease is neoplasm.